CBX6 is suggested to have a tumor suppressor role in CML: CBX6 expression is low in CML, increases during TKI treatment, and CBX6 high CML patients achieve faster complete hematopoietic response than CBX6 low CML patients [31]; CBX6 is not important for hematopoietic progenitors in MDS patients; CBX6‐KD does not affect HSPCs and does not induce differentiation [32]. This evidence concerns the gene CBX6 and myelodysplastic syndrome.